Negative impact of chemotherapy on breast cancer patients QOL - Utility of antiemetic treatment guidelines and the role of race

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 6, 2010, Pages 1523-1527

  Hassan, Bassam Abdul Rasool ^a   Yusoff, Zuraidah Binti Mohd ^a  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

Author keywords

Acute; CINV; Delayed; Genetic polymorphisms; Malaysia; QOL; Races

Indexed keywords

EID: 79956158979     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bloechl-Daum B, Deuson RR, Mavros P, et al (2006). Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol, 24, 4472-8.
2. Cohen L, De Moor CA, Eisenberg P, et al (2007). Chemotherapyinduced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings. Support Care Cancer, 15, 497-503.
3. Das Gupta K, Hossain AKMM, Jaigirdar AR, et al (2007). Effects of ondansetron alone and in combination with domperidone in the prevention of chemotherapy-induced nausea and vomiting in breast cancer patients. Bangladesh J Pharmacol, 2, 13-9.
4. Grunberg SM (2004). Chemotherapy induced nausea and vomiting: prevention, detection and treatment-how are you doing? J Support Oncol, 2, 1-12.
5. Hesketh PJ (2005). Management of nausea and vomiting in cancer treatment: introduction, scope of the problem. In: Management of nausea and vomiting in cancer and cancer treatment eds hesketh PJ. J Bartlett Publishers, 1-14.
6. Huang P, Zhu B, Wang LS, et al (2003). Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women. Eur J Clin Pharmacol, 59, 471-6.
7. Lindley C, Goodin S, Mccune J, et al (2005). Prevention of delayed chemotherapy-induced nausea and vomiting after moderately to highly emetogenic chemotherapy comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol, 28, 270-6.
8. Molassiotis A, Mok TS, Yam BM, et al (2002). An analysis of the antiemetic protection of metoclopramide plus dexamethasone in Chinese patients receiving moderately high emetogenic chemotherapy. Eur J Cancer Care, 11, 108-3.
9. Neymark N, Crott R (2005). Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials. Support Care Cancer, 13, 812-8.
10. Rais N, Chawla YK, Kohli KK (2006). CYP3A phenotypes and genotypes in north Indians. Eur J Clin Pharmacol, 62, 417-22.
11. Ruzilawati AB, Mohd Suhaimi AW, Gan SH (2007). Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. Clinica Chimica Acta, 383, 158-62.
12. Rogers BB (2009). Chemotherapy induce nausea and vomiting. Supportive Care, 18-22.
13. Schnell FM (2003). Chemotherapy induce nausea and vomiting: the importance of acute antiemetic control. Oncologist, 8, 187-98.
14. Yang YS, Wong LP, Lee TC, et al (2004). Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br J Clin Pharmacol, 58, 332-5.